Jaynes J M, Burton C A, Barr S B, Jeffers G W, Julian G R, White K L, Enright F M, Klei T R, Laine R A
Department of Biochemistry, Louisiana State University, Baton Rouge 70803.
FASEB J. 1988 Oct;2(13):2878-83. doi: 10.1096/fasebj.2.13.3049204.
Plasmodium falciparum and Trypanosoma cruzi were killed by two novel lytic peptides (SB-37 and Shiva-1) in vitro. Human erythrocytes infected with P. falciparum, and Vero cells infected with T. cruzi, were exposed to these peptides. The result, in both cases, was a significant decrease in the level of parasite infection. Furthermore, the peptides had a marked cytocidal effect on trypomastigote stages of T. cruzi in media, whereas host eukaryotic cells were unaffected by the treatments. In view of the worldwide prevalence of these protozoan diseases and the lack of completely suitable treatments, lytic peptides may provide new and unique chemotherapeutic agents for the treatment of these infections.
恶性疟原虫和克氏锥虫在体外被两种新型溶细胞肽(SB - 37和Shiva - 1)杀死。将感染恶性疟原虫的人类红细胞以及感染克氏锥虫的Vero细胞暴露于这些肽中。在这两种情况下,结果都是寄生虫感染水平显著降低。此外,这些肽对培养基中克氏锥虫的无鞭毛体阶段具有明显的杀细胞作用,而宿主真核细胞不受这些处理的影响。鉴于这些原生动物疾病在全球的流行以及缺乏完全合适的治疗方法,溶细胞肽可能为治疗这些感染提供新的独特化疗药物。